An investigational product called Acellular Tissue Engineered Vessel demonstrated superior hemodialysis vascular access outcomes compared with AVFs in a phase 3 trial. A bioengineered human tissue ...
Please provide your email address to receive an email when new articles are posted on . At the time of hemodialysis initiation, more than half of patients had an arteriovenous fistula. Fistula use ...
Study evaluates whether Amplifi therapy enables AVF maturation at two weeks, potentially reducing catheter dependence and transforming the dialysis access pathway BOSTON, May 19, 2026 /PRNewswire/ -- ...
Amplifi Vascular announced the initiation of the AMPLIFI-1 pivotal trial evaluating the safety and effectiveness of the Amplifi vei ...
Humacyte, Inc. announced the results of its V007 Pivotal Phase 3 clinical trial for its acellular tissue engineered vessel (ATEV™), focused on arteriovenous access in patients with end-stage renal ...
In a trial, an acellular tissue engineered vessel had superior functional patency for hemodialysis with acceptable safety compared with an arteriovenous fistula in high-risk patients. An acellular ...
TEMPE, Ariz.--(BUSINESS WIRE)--Tempe-based interventional nephrologists Randy Cooper, MD and Umar Waheed, MD, and their team at SKI Vascular Center, this week became the first ambulatory surgical ...
This requires durable access to a blood vessel site where the dialysis machine can remove and return blood. Such access is created when a surgeon attaches a vein to an artery in the patient. The ...
Please provide your email address to receive an email when new articles are posted on . Many variables make accurate prediction of hemodialysis start and AVF maturation nearly impossible. Several ...
Despite all the progress achieved since Scribner first introduced the arteriovenous (AV) shunt in 1960 and Cimino and Brescia introduced the native AV fistula in 1962, we have continued to face a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results